NCT02352675View on ClinicalTrials.gov

Determination of the Minimal Concentration of Antifibrinolytics Required to Inhibit t-PA-activated Fibrinolysis

CompletedOBSERVATIONAL
Enrollment

40

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

March 31, 2016

Study Completion Date

March 31, 2016

Conditions
Congenital Heart DiseaseFibrinolysisRotational Thromboelastometry
Interventions
OTHER

Intraoperative Blood Sample

Blood sample will be run using rotational thromboelastometry to determine the minimal concentration of TXA and EACA need to inhibit fibrinolysis

Trial Locations (1)

02115

Boston Children's Hospital, Boston

All Listed Sponsors
lead

Boston Children's Hospital

OTHER

NCT02352675 - Determination of the Minimal Concentration of Antifibrinolytics Required to Inhibit t-PA-activated Fibrinolysis | Biotech Hunter | Biotech Hunter